论文部分内容阅读
目的:分析门冬胰岛素30联合格华止用于2型糖尿病患者的治疗效果。方法:选取2012年3月-2014年3月来本院内分泌科门诊接受治疗的100例2型糖尿病患者作为研究对象,每组50例,分为研究组和对照组,分别给予门冬胰岛素30联合格华止或单独门冬胰岛素30进行治疗,比较两组患者的治疗前后的空腹血糖、餐后2h血糖及糖化血红蛋白等研究指标。结果:治疗后不论是空腹血糖、餐后2h血糖还是糖化血红蛋白指标,均有不同程度改善,且研究组改善程度均优于对照组,差别有统计学意义(P<0.05),在观察血糖达标时间上,研究组(5.1±2.3)d明显优于对照组(8.8±1.2)d,差异有统计学意义(P<0.05)。结论:门冬胰岛素30联合格华止治疗2型糖尿病效果明显,控制血糖安全性高,值得在临床推广。
OBJECTIVE: To analyze the therapeutic effect of insulin aspart 30 in combination with gehua only for type 2 diabetes mellitus. Methods: From March 2012 to March 2014, 100 cases of type 2 diabetes mellitus received endocrinology outpatient treatment in our hospital were selected as research objects, 50 cases in each group. The patients were divided into study group and control group, Combined with Gehua only or aspart insulin 30 for treatment, fasting blood glucose, postprandial 2h glucose and glycosylated hemoglobin were compared before and after treatment. Results: After treatment, both fasting blood glucose, postprandial blood glucose 2h or glycosylated hemoglobin index improved in varying degrees, and the improvement in the study group were better than the control group, the difference was statistically significant (P <0.05), observed in blood glucose compliance Time, the study group (5.1 ± 2.3) d was significantly better than the control group (8.8 ± 1.2) d, the difference was statistically significant (P <0.05). Conclusion: Aspart 30 insulin combined with Grifar in the treatment of type 2 diabetes mellitus has obvious effect and high blood sugar control, which is worthy of clinical promotion.